Rapt Therapeutics (RAPT) Projected to Post Quarterly Earnings on Thursday

Key Points

• Rapt Therapeutics is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.68) per share.
• The company recently received multiple upgrades from analysts, including a "strong-buy" rating and a price target of $31 from Lifesci Capital.
• Invesco Ltd. significantly increased its stake in Rapt Therapeutics by 411.7%, reflecting growing institutional interest in the company.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Rapt Therapeutics to post earnings of ($0.61) per share for the quarter.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.04). On average, analysts expect Rapt Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapt Therapeutics Stock Performance

NASDAQ RAPT traded down $0.44 during trading on Friday, hitting $9.81. The stock had a trading volume of 25,131 shares, compared to its average volume of 94,652. The company has a market capitalization of $162.26 million, a PE ratio of -0.69 and a beta of 0.01. The company's 50-day moving average price is $9.45 and its two-hundred day moving average price is $8.79. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $26.56.

Analyst Upgrades and Downgrades

RAPT has been the topic of several recent analyst reports. Wall Street Zen lowered Rapt Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Wells Fargo & Company reaffirmed an "overweight" rating and set a $38.00 price target (down previously from $51.00) on shares of Rapt Therapeutics in a research report on Friday. JPMorgan Chase & Co. raised Rapt Therapeutics from an "underweight" rating to a "neutral" rating and set a $14.00 price target on the stock in a research report on Wednesday, July 30th. HC Wainwright boosted their price target on Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. Finally, UBS Group lowered their price target on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $21.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Rapt Therapeutics stock. AQR Capital Management LLC bought a new position in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 154,327 shares of the company's stock, valued at approximately $188,000. AQR Capital Management LLC owned about 0.12% of Rapt Therapeutics at the end of the most recent quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.